Payment overview · 2025
General Payments
$109.48
5 reported records · 5 companies
Healthcare provider profile · identity verified
Timothy L Jackson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BEAVER, PA · NPI 1427070747
Verified facts
What the public records show
CMS Open Payments records show Timothy L Jackson, MD received $109.48 in general payments during 2025 across 5 reported records.
Recor Medical Inc accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Recor Medical Inc | Unresolved — no canonical attribution shown | $28.13 | 25.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.64 | 19.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.93 | 19.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.07 | 18.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.71 | 17.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.48 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
140 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1279 | 251 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1274 | 250 |
| Furosemide | Furosemide | 710 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 697 | 130 |
| Omeprazole | Omeprazole | 696 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 537 | 104 |
| Potassium Chloride | Potassium Chloride | 530 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 439 | 84 |
| Irbesartan | Irbesartan | 430 | 106 |
| Simvastatin | Simvastatin | 430 | 98 |
| Lisinopril | Lisinopril | 428 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 90 |
| Eliquis | Apixaban | 422 | 73 |
| Metformin Hcl | Metformin Hcl | 384 | 98 |
| Sertraline Hcl | Sertraline Hcl | 370 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 366 | 73 |
| Alprazolam | Alprazolam | 303 | 75 |
| Donepezil Hcl | Donepezil Hcl | 302 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 47 |
| Gabapentin | Gabapentin | 271 | 40 |
| Losartan Potassium | Losartan Potassium | 250 | 54 |
| Carvedilol | Carvedilol | 237 | 44 |
| Mirtazapine | Mirtazapine | 199 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 31 |
| Alendronate Sodium | Alendronate Sodium | 172 | 39 |
| Ozempic | Semaglutide | 172 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 170 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 34 |
| Tramadol Hcl | Tramadol Hcl | 168 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 40 |
| Prednisone | Prednisone | 158 | 75 |
| Memantine Hcl | Memantine Hcl | 151 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 32 |
| Montelukast Sodium | Montelukast Sodium | 146 | 37 |
| Synthroid | Levothyroxine Sodium | 140 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 139 | 27 |
| Atenolol | Atenolol | 137 | 26 |
| Risperidone | Risperidone | 134 | 17 |
| Allopurinol | Allopurinol | 133 | 34 |
| Xarelto | Rivaroxaban | 130 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 126 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 89 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 26 |
| Famotidine | Famotidine | 119 | 20 |
| Trazodone Hcl | Trazodone Hcl | 117 | 26 |
| Finasteride | Finasteride | 115 | 24 |
| Loperamide | Loperamide Hcl | 110 | 60 |
| Jardiance | Empagliflozin | 104 | 25 |
| Valsartan | Valsartan | 101 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 19 |
| Lorazepam | Lorazepam | 94 | 23 |
| Cefdinir | Cefdinir | 92 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 26 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 86 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 80 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 20 |
| Bumetanide | Bumetanide | 74 | 13 |
| Myrbetriq | Mirabegron | 73 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | suppressed |
| Glipizide | Glipizide | 72 | 17 |
| Celecoxib | Celecoxib | 71 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 25 |
| Nystatin | Nystatin | 61 | 33 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 20 |
| Meloxicam | Meloxicam | 52 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 39 |
| Naproxen | Naproxen | 49 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 47 |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Verapamil Er | Verapamil Hcl | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Lumigan | Bimatoprost | 44 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 43 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Digoxin | Digoxin | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Felodipine Er | Felodipine | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Carbamazepine Er | Carbamazepine | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 14 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Ssd | Silver Sulfadiazine | 23 | 19 |
| Azithromycin | Azithromycin | 22 | 21 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Fentanyl | Fentanyl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Brinzolamide | Brinzolamide | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.48 · 5 records | Recor Medical Inc | FREESTYLE LIBRE 3, OTEZLA, Ozempic, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error